Summary of COVID-19 zafirlukast studies

1. Ghobain et al., The efficacy of Zafirlukast as a SARS-CoV-2 helicase inhibitor in adult patients with moderate COVID-19 Pneumonia (pilot randomized clinical trial)

40 patient zafirlukast late treatment RCT: 100% higher ICU admission (p=1), 9% worse 7-point scale results (p=0.48), 15% longer hospitalization (p=0.47), and 23% worse viral clearance (p=0.48).
RCT 40 hospitalized patients with moderate COVID-19 pneumonia showing no significant difference with zafirlukast treatment compared to placebo. Authors suggest that the lack of efficacy might be related to timing of drug administration relative to symptom onset or insufficient dosing.
Dec 2022, J. Infection and Public Health, https://www.sciencedirect.com/science/article/pii/S1876034122003094, https://c19p.org/ghobain